days 29 in the closure group vs 17 in the medical therapy group p 017 Mean reduction in migraine with aura days 24 in the closure group vs 06 in the medical therapy group p 001 ID: 933258
Download Presentation The PPT/PDF document "PRIMA Mean reduction in migraine" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
PRIMA
Mean
reduction in migraine days: -2.9 in the closure group vs. -1.7 in the medical therapy group (p = 0.17)Mean reduction in migraine with aura days: -2.4 in the closure group vs. -0.6 in the medical therapy group (p = 0.01) Mean reduction in migraine with aura attacks: -2.0 vs. -0.5 (p < 0.01), respectively
Trial design: Participants with patent foramen ovale (PFO) and migraine headache refractory to medical therapy were randomized to closure with the Amplatzer device (n = 53 [device actually implanted in 41 participants]) vs. ongoing medical therapy (n = 54).
Results
Conclusions
Among patients with PFO and migraine headache refractory to medical therapy, PFO closure did not reduce the total migraine days compared with medical therapyPFO closure was associated with a reduction in migraine with aura days (secondary outcome)
Presented by Dr. David Hildick-Smith at TCT 2014
(p
= 0.17)
PFO closure
-2.9
-1.7
Medical therapy
Mean reduction in migraine days